Sun Pharmaceutical Industries today announced that Sun Pharma has received the Australian Therapeutic Goods Administration (TGA) approval for its speciality product, ILUMYA™ (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of proinflammatory cytokines and chemokines. ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients in ILUMYATM, and in patients with clinically important active infections, e.g. active tuberculosis.

''We are pleased to have received this approval and look forward to bringing ILUMYATM to dermatologists and patients in Australia,'' said Hellen De Kloet, Business Head, Western Europe & Australia, Sun Pharma. ''We are launching a patient support program to assist patients prescribed with ILUMYA™. The program is designed to supplement the support offered by doctors in their practice or in hospital departments,'' she added.

Shares of the company declined Rs 8.75, or 1.35%, to trade at Rs 638.55. The total volume of shares traded was 163,817 at the BSE (11.58 a.m., Friday).